Literature DB >> 4670506

In vitro antibiotic susceptibility of pseudomonads other than Pseudomonas aeruginosa recovered from cancer patients.

M R Moody, V M Young, D M Kenton.   

Abstract

The increase in occurrence of infections due to opportunistic gram-negative bacilli in patients with impaired host defenses emphasizes the need for information on the antibiotic susceptibility of the organisms that colonize such patients. During a 20-month period, more than 100 pseudomonads which were not Pseudomonas aeruginosa were recovered from cancer patients at the Baltimore Cancer Research Center. These included P. fluorescens, P. putida, P. multivorans (cepacia), P. maltophilia, P. stutzeri, P. alcaligenes, and P. pseudoalcaligenes. Susceptibility tests with 12 antibiotics indicated that the intraspecies antibiograms for many of these species were more uniform than those of P. aeruginosa. The stability of susceptibility patterns allowed the antibiograms to be used as aids in the preliminary differentiation of these organisms. Variable antibiogram patterns were noted among certain species, i.e., P. fluorescens, P. stutzeri, and P. multivorans, whereas each of the other species had essentially one pattern. These in vitro studies showed that some of the Pseudomonas species other than P. aeruginosa were resistant to a number of antibiotics. Among these were antibiotics that are in general use for P. aeruginosa infections. Such differences in antibiotic susceptibilities emphasize the necessity for careful speciation of this group of microorganisms to assure proper epidemiological documentation of colonization and infection, as well as to ensure therapy with an antimicrobial agent to which the organism is susceptible in vitro.

Entities:  

Mesh:

Substances:

Year:  1972        PMID: 4670506      PMCID: PMC444318          DOI: 10.1128/AAC.2.5.344

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  24 in total

1.  Acute bacterial endocarditis caused by a variant of the genus Herrellea.

Authors:  W B SORRELL; L V WHITE
Journal:  Am J Clin Pathol       Date:  1952-02       Impact factor: 2.493

2.  Pseudomonas cepacia (multivorans) septicaemia in an intensive-care unit.

Authors:  I Phillips; S Eykyn; M A Curtis; J J Snell
Journal:  Lancet       Date:  1971-02-20       Impact factor: 79.321

3.  Hospital infection by Pseudomonas cepacia.

Authors:  D C Speller; M E Stephens; A C Viant
Journal:  Lancet       Date:  1971-04-17       Impact factor: 79.321

4.  Contamination of commercially packaged urinary catheter kits with the pseudomonad EO-1.

Authors:  P C Hardy; G M Ederer; J M Matsen
Journal:  N Engl J Med       Date:  1970-01-01       Impact factor: 91.245

5.  Antimicrobial susceptibility as a diagnostic aid in the identification of nonfermenting gram-negative bacteria.

Authors:  G L Gilardi
Journal:  Appl Microbiol       Date:  1971-11

6.  Antibiotic susceptibility testing by a standardized single disk method.

Authors:  A W Bauer; W M Kirby; J C Sherris; M Turck
Journal:  Am J Clin Pathol       Date:  1966-04       Impact factor: 2.493

7.  Changing ecology of bacterial infections as related to antibacterial therapy.

Authors:  M Finland
Journal:  J Infect Dis       Date:  1970-11       Impact factor: 5.226

8.  Pseudomonas maltophilia infections in man.

Authors:  G L Gilardi
Journal:  Am J Clin Pathol       Date:  1969-01       Impact factor: 2.493

9.  Postoperative urinary-tract infections caused by contaminated irrigating fluid.

Authors:  R G Mitchell; A C Hayward
Journal:  Lancet       Date:  1966-04-09       Impact factor: 79.321

10.  Characterization of Pseudomonas species isolated from clinical specimens.

Authors:  G L Gilardi
Journal:  Appl Microbiol       Date:  1971-03
View more
  17 in total

1.  Antibiotic susceptibility testing of gram-negative nonfermentative bacilli.

Authors:  K A Ruddell; C R Anselmo
Journal:  Antimicrob Agents Chemother       Date:  1975-04       Impact factor: 5.191

2.  Pseudomonas cepacia strains isolated from water reservoirs of unheated nebulizers.

Authors:  S M Gelbart; G F Reinhardt; H B Greenlee
Journal:  J Clin Microbiol       Date:  1976-01       Impact factor: 5.948

3.  Pseudomonas cepacia septic arthritis due to intra-articular injections of methylprednisolone.

Authors:  T Kothari; M P Reyes; N Brooks
Journal:  Can Med Assoc J       Date:  1977-06-04       Impact factor: 8.262

4.  Prevalence of serotypes of Xanthomonas maltophilia from world-wide sources.

Authors:  B Schable; D L Rhoden; W R Jarvis; J M Miller
Journal:  Epidemiol Infect       Date:  1992-04       Impact factor: 2.451

5.  In vitro susceptibility of Xanthomonas (Pseudomonas) maltophilia to newer antimicrobial agents.

Authors:  N Khardori; A Reuben; B Rosenbaum; K Rolston; G P Bodey
Journal:  Antimicrob Agents Chemother       Date:  1990-08       Impact factor: 5.191

6.  Distribution in clinical material and identification of Pseudomonas maltophilia.

Authors:  B Holmes; S P Lapage; B G Easterling
Journal:  J Clin Pathol       Date:  1979-01       Impact factor: 3.411

7.  Serological classification of Xanthomonas maltophilia (Pseudomonas maltophilia) based on heat-stable O antigens.

Authors:  B Schable; D L Rhoden; R Hugh; R E Weaver; N Khardori; P B Smith; G P Bodey; R L Anderson
Journal:  J Clin Microbiol       Date:  1989-05       Impact factor: 5.948

8.  Association of Pseudomonas cepacia with chronic granulomatous disease.

Authors:  E J Bottone; S D Douglas; A R Rausen; G T Keusch
Journal:  J Clin Microbiol       Date:  1975-05       Impact factor: 5.948

9.  Susceptibility of Pseudomonas maltophilia to antimicrobial agents, singly and in combination.

Authors:  T P Felegie; V L Yu; L W Rumans; R B Yee
Journal:  Antimicrob Agents Chemother       Date:  1979-12       Impact factor: 5.191

10.  Characterization of hemolysin in extracellular products of Pseudomonas cepacia.

Authors:  T Nakazawa; Y Yamada; M Ishibashi
Journal:  J Clin Microbiol       Date:  1987-02       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.